The company hopes to submit its lead drug later this year for FDA approval. What these 3 Bay Area biotech companies did to ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare ...

By bolstering immune cells, researchers at ViiV Healthcare in Branford have designed long-acting drugs that prevent infection ...

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

Biotech remains challenged. The S&P 500’s biotech sub-index is down more than 10 per cent this year, while the broader index ...

With our incredible universities, educated workforce and geographic location, I firmly believe Connecticut can be the next ...

Epidermolysis bullosa is a rare and severe skin disease where patients have fragile skin that blisters and tears. A Mt.

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.

In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

A new report from Pitchbook suggests we’re in for a period of more sustainable investing, with VC firms continuing to create ...